Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Sterling Biotech Limited - Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SLTHY STERLINBIO 512299

0
Sterling Biotech Limited - News Clarification

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SLTHY STERLINBIO 512299

0
Sterling Biotech Limited - News Clarification

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SLTHY STERLINBIO 512299

0
Sterling Biotech Limited - Updates

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SLTHY STERLINBIO 512299

0
Rs 5,000 cr bank loan fraud case: Charge sheet against Gujarat-based pharma firm’s director

2018-07-18 freepressjournal.in
New Delhi: The Enforcement Directorate has filed a charge sheet against Gujarat-based pharma firm Sterling Biotech Limited’s director Rajbhushan Omprakash Dixit in a bank loan fraud case of over Rs 5,000 crore. The charge sheet was filed before Additional Sessions Judge Satish Arora by special public prosector Nitesh Rana and advocate A R Aditya.
SLTHY STERLINBIO 512299 532418 ANDHRABANK

0
ED chargesheet against Sterling Biotech director in bank loan fraud case

2018-07-18 livemint
New Delhi: The Enforcement Directorate has filed a chargesheet against Rajbhushan Omprakash Dixit, director of Gujarat-based pharmaceutical firm Sterling Biotech, in a case involving bank loan fraud of over ₹5,000 crore.
SLTHY STERLINBIO 512299 532418 ANDHRABANK

0
Sterling Biotech Limited - News Clarification

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SLTHY STERLINBIO 512299

0
NCLT reserves order on Srei Infra’s plea against Sterling units

2018-07-02 livemint
Mumbai: The Mumbai bench of the National Company Law Tribunal (NCLT) has reserved its order in an insolvency plea filed by Srei Infrastructure Finance Ltd (SIFL) against Sterling SEZ & Infrastructure and Sterling International Enterprises, subsidiaries of Sterling Biotech, a firm that is also admitted for the resolution process. Srei has suggested the name of Vishal Jain as interim resolution professional (IRP) to the tribunal.
SIFLY 508998 523756 STEERINTER SRI SLTHY STERLINBIO SREINFRA 512299 532418 SRIA ANDHRABANK

0
Srei Infra Finance files insolvency plea against two Sandesara firms

2018-06-26 livemint
Mumbai: Srei Infrastructure Finance Ltd has filed an insolvency petition against Sterling SEZ & Infrastructure and Sterling International Enterprises before the Mumbai bench of the National Company Law Tribunal (NCLT).
SIFLY 508998 523756 STEERINTER SRI SLTHY STERLINBIO SREINFRA 512299 532418 SRIA ANDHRABANK

0
Andhra Bank moves NCLT to recover Rs 4,000-crore Sterling Biotech dues

2018-06-12 freepressjournal.in
Mumbai : The National Company Law Tribunal (NCLT) on Monday admitted an insolvency plea filed by Andhra Bank against Sterling Biotech, seeking recovery of Rs 4,000 crore in dues.
SLTHY STERLINBIO 512299 532418 ANDHRABANK

0
Sterling Biotech Limited - News Clarification

2018-06-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SLTHY STERLINBIO 512299

2
Bank fraud: ED attaches Rs 4,701 crore assets of Gujarat pharma firm

2018-06-01 freepressjournal.in
New Delhi: The Enforcement Directorate has attached Rs 4,701 crore worth of assets of Gujarat-based pharmaceutical company Sterling Biotech Group in connection with a Rs 5,000 crore bank fraud money laundering case, the agency said today.
SLTHY STERLINBIO 512299 532480 532418 ALBK 532505 UCOBANK ANDHRABANK SBAZ

0
Three more cos under SFIO lens

2018-05-15 freepressjournal.in
New Delhi : The Serious Fraud Investigation Office (SFIO) is probing three companies — Ruchi Soya, Sterling Biotech and Kanishk Gold — that are already under the regulatory scanner for loan defaults, according to an official source.
SLTHY STERLINBIO RUCHISOYA 512299 500368

0
Sterling Biotech Limited - News Clarification

2018-05-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SLTHY STERLINBIO 512299

0
Sterling Biotech Limited - News Clarification

2018-05-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SLTHY STERLINBIO 512299

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 85916G108